Novo Nordisk GLP-1 competition Warning with new pill rival
Can Novo Nordisk defend its GLP-1 dominance as a potent oral rival emerges and a bold US telehealth deal reshapes distribution? How does Structure Therapeutics challenge Novo Nordisk?…
Novo Nordisk FDA warning: Safety shock and WHO funding pivot
Can the Novo Nordisk FDA warning derail the GLP-1 boom just as a new WHO partnership reshapes the company’s global image? How serious is the Novo Nordisk FDA…
Novo Nordisk Hims partnership Boom: GLP‑1 market power shift
Can the Novo Nordisk Hims partnership turn a legal fight over compounded GLP‑1s into a powerful new growth channel for both sides? How does the Novo Nordisk Hims…